Capital World Investors Purchases 502,627 Shares of Boston Scientific Corporation $BSX

Capital World Investors increased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 1.9% in the 4th quarter, HoldingsChannel reports. The fund owned 27,151,575 shares of the medical equipment provider’s stock after acquiring an additional 502,627 shares during the period. Capital World Investors’ holdings in Boston Scientific were worth $2,588,953,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Capital Research Global Investors raised its stake in shares of Boston Scientific by 6.8% during the 4th quarter. Capital Research Global Investors now owns 7,084,055 shares of the medical equipment provider’s stock worth $675,467,000 after acquiring an additional 450,322 shares in the last quarter. Capital International Sarl increased its stake in Boston Scientific by 26.6% during the 4th quarter. Capital International Sarl now owns 415,718 shares of the medical equipment provider’s stock valued at $39,639,000 after purchasing an additional 87,427 shares in the last quarter. Capital International Ltd. CA increased its stake in Boston Scientific by 17.3% during the 4th quarter. Capital International Ltd. CA now owns 238,865 shares of the medical equipment provider’s stock valued at $22,776,000 after purchasing an additional 35,274 shares in the last quarter. Capital International Inc. CA increased its stake in Boston Scientific by 15.7% during the 4th quarter. Capital International Inc. CA now owns 221,927 shares of the medical equipment provider’s stock valued at $21,161,000 after purchasing an additional 30,194 shares in the last quarter. Finally, Capital Group Investment Management PTE. LTD. increased its stake in Boston Scientific by 19.3% during the 4th quarter. Capital Group Investment Management PTE. LTD. now owns 51,858 shares of the medical equipment provider’s stock valued at $4,945,000 after purchasing an additional 8,396 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Canaccord reiterated a Buy rating on Boston Scientific, even though it trimmed its price target slightly to $70 from $71, signaling continued confidence in the company’s long-term outlook. Is Boston Scientific Corporation (BSX) One of the Top Cheap Stocks With Strong Buy Ratings on Wall Street?
• Positive Sentiment: Truist also kept a Buy rating, though it cut its price target to $64 from $85, suggesting analysts still see meaningful upside despite a more cautious valuation view. Benzinga
• Positive Sentiment: The company announced plans for a $138 million medical device distribution facility in Indiana, which should expand operations and add 300 jobs, a sign of ongoing investment in growth and logistics capacity. Boston Scientific to open $138M medical device distribution facility in Indiana, adding 300 jobs
• Neutral Sentiment: Boston Scientific’s last reported quarter was strong, with revenue of $5.20 billion and EPS of $0.80 beating expectations, but the company also cut guidance due to stronger competition in cardiac devices and slower Watchman growth, creating a mixed fundamental backdrop. How Investors May Respond To Boston Scientific (BSX) Strong Q1 Beat But Cut Guidance On Watchman Growth
• Neutral Sentiment: Recent market commentary noted BSX has been trading above market averages on some sessions, but also lagging some peers, reflecting choppy investor sentiment rather than a clear trend. Boston Scientific Corp. stock underperforms Thursday when compared to competitors despite daily gains
• Negative Sentiment: The repeated reductions in price targets from analysts, including Truist and Canaccord, suggest expectations have reset lower, which can weigh on sentiment even when ratings remain positive. Is Boston Scientific Corporation (BSX) One of the Top Cheap Stocks With Strong Buy Ratings on Wall Street?

Insider Buying and Selling

In other news, Director Edward J. Ludwig purchased 3,580 shares of the stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average cost of $56.68 per share, with a total value of $202,914.40. Following the completion of the acquisition, the director owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. This represents a 16.44% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director David C. Habiger purchased 2,250 shares of the stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the acquisition, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. This represents a 19.35% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders have bought 9,800 shares of company stock valued at $554,012. Corporate insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

BSX has been the topic of a number of recent analyst reports. Truist Financial cut their price target on shares of Boston Scientific from $85.00 to $64.00 and set a “buy” rating on the stock in a research note on Thursday. Barclays cut their price target on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a research note on Thursday, May 28th. Royal Bank Of Canada restated an “outperform” rating on shares of Boston Scientific in a research note on Thursday, May 28th. Canaccord Genuity Group cut their price target on shares of Boston Scientific from $71.00 to $70.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. Finally, Stifel Nicolaus set a $75.00 price target on shares of Boston Scientific in a research note on Wednesday, May 27th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $85.92.

Boston Scientific Stock Down 0.4%

BSX stock opened at $48.66 on Friday. The firm’s fifty day simple moving average is $58.11 and its 200-day simple moving average is $76.70. The company has a market capitalization of $72.32 billion, a P/E ratio of 20.36, a price-to-earnings-growth ratio of 0.91 and a beta of 0.56. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. Boston Scientific Corporation has a 12 month low of $47.17 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 3.37 earnings per share for the current year.

Boston Scientific announced that its Board of Directors has initiated a share buyback program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.